INCIDENCE OF CANCER IN PHYSICAL CHECKUP POPULATION WITH RISING OF SERUM CARCINOEMBRYONIC ANTIGEN
Keywords:
Carcinoembryonic antigen, CEA, tumor marker, cancer screeningAbstract
Carcinoembryonic antigen (CEA) is one of the tumor markers that use for screening colon cancers. However, the evidence-based of CEA in colorectal cancer screening is still not clear. A retrospective cohort study was designed to show incidence of cancer in physical checkup and screening serum CEA populations. Patients who attended physical checkup and screening serum CEA level at Suranaree University of Technology Hospital between January 2015 and January 2017 were enrolled and assigned into high and normal CEA level groups. Of total 310 enrolled participants, the mean plasma CEA levels in high and normal CEA level group were 7.44 and 1.84 ng/ml, respectively. After 12 months of observation, the high CEA level group provided a significance increased rate of cancer compared with a normal CEA group (p=0.03). Five cancers (3.2%) were detected in the high CEA level group at 11, 64, 114, 212 and 361 days and no cancer was detected in a normal CEA level group. In conclusion, patients who had undergone physical checkup and screening CEA, high CEA level patient provided an increased rate of cancer compared with normal CEA level patient.
References
Arnaud, J.P., Koehl, C., and Adloff, M. (1980). Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis. Col. Rect., 23(3):141-144.
Carriquiry, L.A. and Pineyro, A. (1999). Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis. Col. Rect., 42(7):921-929.
Cohen, J.D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A.A., Wong, F., Mattox, A., Hruban, R.H., Wolfgang, C.L., Goggins, M.G., Molin, M.D., Wang, T.-L., Roden, R., Klein, A.P., Ptak, J., Dobbyn, L., Schaefer, J., Silliman, N., Popoli, M., Vogelstein, J.T., Browne, J.D., Schoen, R.E., Brand, R.E., Tie, J., Gibbs, P., Wong, H.-L., Mansfield, A.S., Jen, J., Hanash, S.M., Falconi, M., Allen, P.J., Zhou, S., Bettegowda, C., Diaz Jr.L.A., Tomasetti, C., Kinzler, K.W., Vogelstein, B., Lennon, A.M., and Papadopoulos, N. (2018). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 359(6378):926-930.
Duffy, M.J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., Nilsson, O., Sturgeon, C., and Topolcan, O. (2003). Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer., 39(6):718-727. doi: 10.1016/s0959-8049(02)00811-0.
Duffy, M.J. (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem., 47(4):624-630.
Fletcher, R.H. (1986). Carcinoembryonic antigen. Annal. Int. Med., 104(1):66-73.
Gold, P. and Freedman, S.O. (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med., 121(3):439-462. Doi: 10.1084/Jem.121.3.439.
Haber, D.A. and Velculescu, V.E. (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Disc., 4(6):650-661.
Hine, K.R., Booth, S.N., Leonard, J.C., and Dykes. P.W. (1978). Carcinoembryonic antigen concentrations in undiagnosed patients. Lancet. 2(8104-5):1,337-1,340.
Lin, J.S., Piper, M.A., Perdue, L.A., Rutter, C.M., Webber, E.M., O'Connor, E., Smith, N., and Whitlock, E.P. (2016). Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 315(23): 2,576-2,594.
Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S., Somerfield, M.R., Hayes, D.F., Bast, R.C.Jr. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol., 24(33):5,313-5,327. doi: 10.1200/JCO.2006.08.2644.
Lopes, G., Stern, M.C., Temin, S., Sharara, A.I., Cervantes, A., Costas-Chavarri, A., Engineer, R., Hamashima, C., Ho, G.F., Huitzil, F.D., Moghani, M.M., Nandakumar, G., Shah, M.A., Teh, C., Manjarrez, S.E.V., Verjee, A., Yantiss, R., and Correa, M.C. (2019) Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline. J. Glob. Oncol., 5:1-22.
Merker, J.D., Oxnard, G.R., Compton, C., Diehn, M., Hurley, P., Lazar, A.J., Lindeman, N., Lockwood, C.M., Rai, A.J., Schilsky, R.L., Tsimberidou, A.M., Vasalos, P., Billman, B.L., Oliver, T.K., Bruinooge, S.S., Hayes, D.F., and Turner, N.C. (2018) Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol., 36(16):1,631-1,641.
Neumann, M.H.D., Bender, S., Krahn, T., and Schlange, T. (2018). ctDNA and CTCs in Liquid Biopsy - Current Status and Where We Need to Progress. Comput. Struct. Biotechnol. J., 16:190-195.
Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J., Anagnostou, V., Fiksel, J., Cristiano, S., Papp, E., Speir, S., Reinert, T., Orntoft, M.-B.W., Woodward, B.D., Murphy, D., Parpart-Li, S., Riley, D., Nesselbush, M., Sengamalay, N., Georgiadis, A., Li, Q.K., Madsen, M.R., Mortensen, F.V., Huiskens, J., Punt, C., van Grieken, N., Fijneman, R., Meijer, G., Husain, H., Scharpf, R.B., Diaz, L.A., Jones, Jr, S., Angiuoli, S., Ørntoft, T., Nielsen, H.J., Andersen, C.L., and Velculescu, V.E. (2017). Direct detection of early-stage cancers using circulating tumor DNA. Sci. Trans. Med., 16:9(403):eaan2415.
Provenzale, D., Jasperson, K., Ahnen, D.J., Aslanian, H., Bray, T., Cannon, J.A., David, D.S., Early, D.S., Erwin, D., Ford, J.M., Giardiello, F.M., Gupta, S., Halverson, A.L., Hamilton, S.R., Hampel, H., Ismail, M.K., Klapman, J.B., Larson, D.W., Lazenby, A.J., Lynch, P.M., Mayer, R.J., Ness, R.M., Rao, M.S., Regenbogen, S.E., Shike, M., Steinbach, G., Weinberg, D., Dwyer, M.A., Freedman-Cass, D.A., and Darlow, S. (2015). Colorectal Cancer Screening, Version 1.2015. J. Natl. Compr. Canc. Netw., 13(8):959-968.
Ransohoff, D.F. and Sox, H.C. (2016). Clinical practice guidelines for colorectal cancer screening: new recommendations and new challenges. JAMA., 315(23):2,529-2,531.
Summary of an NIH Consensus Statement. (1981). Carcinoembryonic antigen: its role as a marker in the management of cancer. British Med. J., 282(6,261):373-375.
Thomson DM, Krupey J, Freedman SO, Gold P. (1969). The radioimmunoassay of circulating carcino-embryonic antigen of the human digestive system. Proceedings of the National Academy of Sciences of the United States of America. 64(1):161-167.
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., Davidson, K.W., Epling, J.W. Jr, García, F.A.R., Gillman, M.W., Harper, D.M., Kemper, A.R., Krist, A.H., Kurth, A.E., Landefeld, C.S., Mangione, C.M., Owens, D.K., Phillips, W.R., Phipps, M.G., Pignone, M.P., and Siu, A.L. (2016). Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA., 315(23): 2,564-2,575.
